Search the Newsreel

New Citius Oncology director brings college, legal and bank experience

Treace Medical Concepts, Inc. (NASDAQ:TMCI) Released Earnings Last Week And Analysts Lifted Their Price Target To US$5.50

Treace Medical Concepts (NASDAQ:TMCI) recently released its Q2 earnings, with revenues exceeding expectations at US$45m and statutory losses coming in smaller than anticipated at US$0.24 per share. Following the report, analysts increased their price target for TMCI to US$5.50, reflecting a moderate uplift in …

William Blair Downgrades Cardiff Oncology to Market Perform From Outperform

William Blair has downgraded Cardiff Oncology (CRDF) from an "Outperform" rating to "Market Perform." This comes shortly after Cardiff Oncology reported its earnings results for the second quarter and six months ended June 30, 2026. The company is a clinical-stage biotechnology firm focused on …

Five of 24 glioma patients remain on NeOnc’s at-home nasal therapy

NeOnc Technologies reported positive topline Phase 2a results for its intranasal NEO100 therapy in patients with recurrent IDH1-mutant high-grade glioma, meeting its primary endpoint with a six-month progression-free survival of 48.9%. The therapy showed encouraging median overall survival of 26.09 months and was well-tolerated …

Is Concentra Group Holdings Parent (CON) Undervalued Following Strong Earnings And Raised Guidance?

Solid Earnings Reflect BeOne Medicines' (NASDAQ:ONC) Strength As A Business

Racura Oncology Ltd (ASX:RAC) Falls — Is the Company Formerly Known as Race Oncology Facing Its First Big Investor Test?

HC Wainwright Issues Pessimistic Outlook for CGEM Earnings

How (PDLB) Movements Inform Risk Allocation Models

This article analyzes Ponce Financial Group Inc. (NASDAQ: PDLB) using AI models, highlighting a weak near-term sentiment despite long-term strength. It outlines three distinct institutional trading strategies—Position, Momentum Breakout, and Risk Hedging—tailored for different risk profiles. The analysis also provides multi-timeframe signal analysis, showing …

Concentra Group Holdings Parent, Inc. Stock 12‑Month Price Target Raised to $39.12, Implies 18% Upside

The average 12-month price target for Concentra Group Holdings Parent, Inc. stock has been raised from $38.62 to $39.12 by 8 analysts, with a range of $34 to $42. This new target implies an 18% potential upside based on the Aug. 11 closing price. …

Alphamab Oncology Sets Board Meeting to Approve 2026 Interim Results

William Blair downgrades Cardiff Oncology stock rating on rights uncertainty

William Blair has downgraded Cardiff Oncology (NASDAQ: CRDF) from Outperform to Market Perform, citing material deterioration in company fundamentals and uncertainty surrounding onvansertib rights. This downgrade follows Cardiff’s Q2 financial results and business update, with the stock already down 63% year-to-date and the company …

Once Upon A Farm: Volume Surges 40% As Revenue Jumps 42% To $85.4 Million

Once Upon a Farm reported a significant volume-driven growth in Q2 2026, with net sales increasing by 42.3% to $85.4 million and product volume surging by 40.3%. The company's IPO in February led to a strong balance sheet, with cash and equivalents reaching $93.5 …

Cardiff Oncology (NASDAQ: CRDF) cuts R&D spend but flags going concern risk

Cardiff Oncology reported a Q2 2026 net loss of $9.2 million and a six-month operating cash outflow of $24.1 million, reducing R&D expenses by cutting clinical trials and preclinical work. The company raised $10.1 million in a direct offering but issued a "going concern" …

Concord Enviro Systems Publishes Q1 FY27 Investor Presentation

CGON (CGON) insider Ambaw Bellete plans 50,000-share stock sale

CG Oncology (CGON) insider Ambaw Bellete plans to sell 50,000 shares of common stock on August 11, 2026, through a stock option exercise settled in cash. The estimated value of this planned sale is $3,810,255.00. This disclosure also reveals several recent sales of CGON …

Cardiff Oncology earnings missed by $0.02, revenue topped estimates

Cardiff Oncology: Q2 Earnings Snapshot

Cardiff Oncology, Inc. (CRDF) reported a Q2 loss of $9.2 million, or 14 cents per share, surpassing Wall Street expectations that predicted a loss of 17 cents per share. The company achieved revenue of $104,000, which met Street forecasts. This financial summary was generated …

Two July Hires Receive Options on 65,350 BridgeBio Shares

BridgeBio Oncology Therapeutics (NASDAQ: BBOT) announced it granted inducement equity awards on August 10, 2026, to two new employees hired in July 2026. These employees received non-qualified stock options for an aggregate of 65,350 shares of common stock at an exercise price of $9.28 …

BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

BridgeBio Oncology Therapeutics (BBOT) announced inducement grants of non-qualified stock options to two new employees hired in July 2026. These grants, totaling 65,350 shares at an exercise price of $9.28 per share, were made under BBOT’s 2025 Inducement Plan and approved in accordance with …

Cardiff Oncology (NASDAQ:CRDF) Releases Earnings Results, Misses Expectations By $0.02 EPS

Cardiff Oncology (NASDAQ:CRDF) reported a quarterly loss of $0.14 per share, missing analyst expectations by $0.02, despite revenue of $0.10 million surpassing the consensus estimate. The company's shares are trading under pressure, well below moving averages, and analysts generally hold a "Hold" rating. Despite …

Cardiff Oncology Reports Second Quarter 2026 Results and Provides Business Update

Cardiff Oncology announced its second quarter 2026 financial results and provided a business update, highlighting positive Phase 2 data for its drug onvansertib in first-line RAS-mutated metastatic colorectal cancer. The company plans to initiate a registrational Phase 3 trial in Q1 2027, pending additional …

BridgeBio Oncology Therapeutics (NASDAQ: BBOT) doubles R&D spend, logs $98.6M loss

BeiGene, Ltd. (NASDAQ: ONC) Share Price, ONC Stock News, ONC Share Price & Updates

Cullinan Oncology stock hits 52-week high at 19.43 USD By Investing.com

Cullinan Oncology (CGEM) stock has reached a new 52-week high of $19.43, reflecting a substantial increase of approximately 158% over the past year. The company's market capitalization now stands at $1.24 billion, driven by strong investor confidence and recent positive developments. These include favorable …

Once Upon A Farm (NYSE:OFRM) Stock Price Down 5.8% - Time to Sell?

CG Oncology (NASDAQ:CGON) Hits New 52-Week High - Should You Buy?

CG Oncology (NASDAQ:CGON) recently reached a new 52-week high of $77.49, with a current trading price near $76.98. The clinical-stage biopharmaceutical company has a "Moderate Buy" consensus rating from analysts, with several price target increases, but reported a quarterly loss of $0.90 per share, …

Is ALX Oncology Holdings (ALXO) Stock Outpacing Its Medical Peers This Year?

The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Is ALX Oncology Holdings Inc. (ALXO) one of those stocks right now? A quick glance at the company's year-to-date performance in comparison to …

NTHI Brain Cancer Phase 2 Data Expected to Spark Triple Confluence

NeOnc Technologies Holdings (NASDAQ: NTHI) is anticipated to release topline Phase 2a results for its intranasal NEO100 therapy for recurrent IDH1-mutant high-grade glioma on August 12. Market observers are noting a "triple confluence setup" for a potential high-impact catalyst, considering the stock's recent 52-week …

Concord Healthcare Schedules Board Meeting to Review Interim Results and Dividend

$NeOnc Technologies (NTHI.US)$@Trytosaveabit and thats 10% ROI! thanks for the heads-up! [Cool Guy]

A user named AigooHensemboi thanks another user, Trytosaveabit, for a heads-up on NeOnc Technologies (NTHI.US), which resulted in a 10% return on investment (ROI). The post is a brief message from the Moomoo community feed, highlighting a positive trading outcome.

Citius Oncology (CTOR) Expected to Announce Earnings on Tuesday

Citius Oncology (NASDAQ:CTOR) is anticipated to release its Q3 2026 earnings before market open on Tuesday, August 18th, with analysts forecasting a loss of $0.04 per share and revenue of $5.83 million. The upcoming earnings call is scheduled for August 21st. The company's previous …

Neo-Concept International (NCI) CFO Peter Pang files initial Form 3 ownership

Neo-Concept International Group Holdings Ltd's CFO, Peter Chun Ming Pang, has filed an initial Statement of Beneficial Ownership (Form 3) with the SEC. This filing indicates his position as an officer but does not report any actual holdings or transactions at this time. The …

ALX Oncology Holdings Inc reports results for the quarter ended June 30 - Earnings Summary

ALX Oncology Holdings Inc has released its earnings summary for the quarter that ended on June 30. The article is a brief announcement of these results, directing readers to access the full report on TradingView, which aggregates content from Reuters and other news sources.

Treace Medical Concepts, Inc. (NASDAQ:TMCI) Given Consensus Rating of "Reduce" by Analysts

Analysts have issued a consensus "Reduce" rating for Treace Medical Concepts, Inc. (NASDAQ:TMCI), with an average 12-month price target of $5.17, despite the company beating recent quarterly revenue and EPS estimates. The stock opened at $4.67, and significant insider and institutional ownership is noted. …

Kura Oncology Announces Publication in Blood Highlighting Ziftomenib’s Differentiated Binding Profile and Preclinical Activity

Kura Oncology announced the publication of a manuscript in Blood detailing the discovery and preclinical development of ziftomenib, a menin inhibitor approved by the FDA for relapsed or refractory NPM1-mutated acute myeloid leukemia (AML). The publication highlights ziftomenib's differentiated binding profile, potent and selective …